SK bioscience’s vaccine heart is seen on this undated picture, Andong, North Gyeongsang Province. Courtesy of SK bioscience
SK bioscience, a biopharmaceutical arm of Korea’s SK Group, stated Wednesday it would provide 750,000 doses of influenza vaccines to the southern hemisphere market within the first half.
The newest deal marks SK bioscience’s second export of influenza vaccines to the southern hemisphere market, together with Southeast Asia and Latin America, following its cargo to Thailand final 12 months, the corporate stated in a press launch.
SKYCellflu, launched by SK bioscience in 2016, is the world’s first cell culture-based influenza vaccine, which has obtained the World Well being Group’s (WHO) prequalification (PQ) certification, it stated.
The corporate produces the vaccine product at its home manufacturing facility L HOUSE in Andong, 188 kilometers south of Seoul.
„Our independently developed vaccines have already confirmed their competitiveness within the international market by buying WHO PQ certification. With these vaccines, we are going to proceed increasing our international presence,“ SK bioscience Chief Govt Officer Ahn Jae-yong stated within the launch. (Yonhap)
